Stomach pain is one of the most frequently reported side effects of Wegovy (semaglutide). For most people, it is mild, tied to dose increases, and fades within a few weeks. However, certain patterns of pain — especially severe, sudden, or persistent discomfort — can signal a serious condition that requires prompt medical attention.

Why Does Wegovy Cause Stomach Pain?

Wegovy works partly by slowing the rate at which your stomach empties food into the small intestine, a process called gastric emptying. According to the FDA prescribing information for Wegovy, this mechanism is responsible for much of the gastrointestinal (GI) discomfort users experience. When food sits in the stomach longer than usual, it can cause:

  • Nausea and vomiting
  • Bloating and a feeling of fullness
  • Cramping or dull aching in the upper or middle abdomen
  • Belching and indigestion

These effects are most noticeable in the first few weeks after starting the medication or after each dose escalation. In the STEP 1 clinical trial published in the New England Journal of Medicine (Wilding et al., 2021), nausea was reported by about 44% of semaglutide participants and abdominal pain by roughly 20%, compared to much lower rates in the placebo group.

What Does Normal Wegovy Stomach Pain Look Like?

Typical, expected stomach discomfort from Wegovy tends to share several features that distinguish it from something more serious:

  • Mild to moderate intensity — uncomfortable but manageable without emergency care
  • Tied to eating — usually worse right after meals, especially large or fatty ones
  • Comes and goes — not constant, and often improves with smaller portions or slower eating
  • Improves over time — typically peaks in the first 1–4 weeks of a new dose and then eases
  • Accompanied by common GI symptoms — nausea, bloating, or loose stools rather than fever or severe pain

Eating smaller meals, avoiding high-fat foods, staying upright after eating, and drinking plenty of water are strategies commonly recommended to manage this kind of discomfort.

Week-by-Week Timeline: When to Expect GI Side Effects

Weeks on Current Dose Typical GI Experience What Helps
Weeks 1–2 Nausea, mild cramping, and bloating are most intense Small meals, low-fat foods, ginger tea
Weeks 3–4 Symptoms often plateau then begin to ease Continue meal adjustments; stay hydrated
Weeks 5–8 Most people notice significant improvement Gradual reintroduction of normal diet
After each dose increase Symptoms may temporarily return at previous week 1–2 intensity Same strategies as initial weeks
Maintenance dose (17 mg) GI symptoms typically stable and mild for most users Consistent eating habits

Most important point: Severe abdominal pain that radiates to your back, is accompanied by vomiting you cannot control, or comes on suddenly and does not improve within a few hours is never normal with Wegovy. These symptoms can indicate pancreatitis — a potentially life-threatening inflammation of the pancreas — and require emergency evaluation immediately.

When Should You Call Your Doctor?

The FDA prescribing information for Wegovy lists several serious GI conditions as risks. Contact your healthcare provider promptly — or go to an emergency room — if you experience any of the following:

  • Severe upper abdominal pain radiating to your back — a hallmark symptom of pancreatitis
  • Persistent vomiting that prevents you from keeping fluids down for more than 24 hours
  • Signs of dehydration — dark urine, dizziness, dry mouth, rapid heart rate
  • Pain that is constant rather than coming in waves
  • Fever alongside abdominal pain — may suggest infection or bowel obstruction
  • Blood in your stool or vomit
  • Sudden inability to pass stool or gas — a possible sign of ileus (intestinal blockage), which the FDA flagged in a 2023 safety review of GLP-1 medications

Are There Longer-Term Stomach Risks to Know About?

Beyond short-term discomfort, two longer-term GI concerns are worth understanding. First, gastroparesis — severely delayed stomach emptying — has been reported in some GLP-1 users, though a confirmed causal link has not been definitively established. The FDA began reviewing these reports in 2023. Second, semaglutide carries a warning about acute pancreatitis in its labeling. While the absolute risk is low, people with a personal or family history of pancreatitis, gallstones, or heavy alcohol use should discuss their risk with their prescriber before starting Wegovy. If you have had pancreatitis in the past, Wegovy may not be appropriate for you.

Frequently Asked Questions

For most people, the worst stomach pain occurs in the first one to four weeks after starting a new dose. As your body adjusts, symptoms typically ease considerably by weeks five through eight. Each time your dose is increased on the standard escalation schedule, mild discomfort may temporarily return before settling again.
Over-the-counter antacids or anti-nausea medications are sometimes recommended for mild discomfort, but you should ask your prescriber before taking anything new. NSAIDs like ibuprofen can irritate the stomach lining, which may make GI symptoms worse. Your provider is the best person to guide you on what is safe to combine with your medication.
The injection site — abdomen, upper arm, or thigh — does not meaningfully change the GI side effect profile, as semaglutide's effects on the stomach are systemic rather than local. Rotating injection sites is recommended by the FDA prescribing information mainly to prevent skin reactions, not to reduce nausea or stomach pain.
High-fat, greasy, or fried foods tend to worsen stomach pain and nausea because they already slow digestion on their own — compounding the gastric emptying delay caused by semaglutide. Very spicy foods, large meal portions, carbonated drinks, and alcohol are also commonly reported triggers. Eating slowly and stopping when comfortably full can make a notable difference.
Do not stop Wegovy on your own without speaking to your prescriber first. For mild to moderate discomfort, your provider may suggest dietary changes, delaying the next dose increase, or staying at your current dose longer. If pain is severe or accompanied by warning signs, seek medical care immediately — but still loop your prescriber in as soon as possible.
Ulcers are not listed as a known risk in the FDA prescribing information for Wegovy. However, the FDA has been reviewing post-market reports of gastroparesis — significantly slowed stomach emptying — in some people using GLP-1 receptor agonists. If you have a history of gastroparesis or stomach motility problems, discuss this with your prescriber before starting treatment.
GI side effects in the STEP 1 trial (Wilding et al., 2021) were most common during the dose escalation phase, meaning symptoms often flare temporarily each time the dose goes up. Once you stabilize at a given dose, most people find the discomfort diminishes. The slow escalation schedule built into Wegovy's dosing protocol is specifically designed to minimize this effect.

Stomach pain on Wegovy is a real and common experience, but it exists on a spectrum — from the minor bloating that eases after a few weeks, to rare but serious conditions that need urgent care. Keeping a simple log of when pain occurs, how intense it is, and what you ate can be a practical way to spot patterns and share useful information with your healthcare provider. Your prescriber can help you weigh whether to adjust your dose, change your eating habits, or investigate further. Never hesitate to reach out to them with concerns, especially if something feels different or more severe than usual.

Sources
  • FDA Wegovy (semaglutide) Prescribing Information, 2023
  • Wilding JPH, et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  • NIH National Institute of Diabetes and Digestive and Kidney Diseases. 'Pancreatitis.' https://www.niddk.nih.gov/health-information/digestive-diseases/pancreatitis
  • FDA Drug Safety Communication: Ozempic, Wegovy, and gastroparesis. 2023

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.